Journal article
Functional interdependence of BRD4 and DOT1L in MLL leukemia
Omer Gilan, Enid YN Lam, Isabelle Becher, Dave Lugo, Ester Cannizzaro, Gerard Joberty, Aoife Ward, Meike Wiese, Chun Yew Fong, Sarah Ftouni, Dean Tyler, Kym Stanley, Laura MacPherson, Chen-Fang Weng, Yih-Chih Chan, Margherita Ghisi, David Smil, Christopher Carpenter, Peter Brown, Neil Garton Show all
Nature Structural & Molecular Biology | NATURE PUBLISHING GROUP | Published : 2016
DOI: 10.1038/nsmb.3249
Grants
Awarded by National Health and Medical Research Council of Australia
Awarded by AbbVie
Awarded by Bayer
Awarded by Lilly Canada
Awarded by Novartis Research Foundation
Awarded by Ontario Ministry of Economic Development and Innovation
Awarded by Pfizer
Awarded by Takeda
Awarded by Wellcome Trust
Awarded by Boehringer Ingelheim
Awarded by Genome Canada through the Ontario Genomics Institute
Awarded by GlaxoSmithKline
Awarded by Cancer Research UK
Awarded by Medical Research Council
Awarded by Worldwide Cancer Research
Funding Acknowledgements
A postdoctoral Fellowship awarded to O.G. from Leukaemia Foundation Australia partly supported this work. A mid-career Fellowship awarded to E.Y.N.L. from the Victoria Cancer Agency partly supported this work. A Senior Leukaemia Foundation Australia Fellowship and VESKI Innovation Fellowship currently support M.A.D. The National Health and Medical Research Council of Australia (1066545 (M.A.D.), 1085015 (M.A.D.), 1106444 (M.A.D.)) and Leukaemia Foundation Australia fund M.A.D.'s laboratory. This work was also funded in part by the Structural Genomics Consortium, a registered charity (no. 1097737) that received funds from AbbVie; Bayer; Boehringer Ingelheim; Genome Canada through the Ontario Genomics Institute (OGI-055); GlaxoSmithKline; Janssen; Lilly Canada; the Novartis Research Foundation; the Ontario Ministry of Economic Development and Innovation; Pfizer; Takeda; and the Wellcome Trust (092809/Z/10/Z).